期刊文献+
共找到5篇文章
< 1 >
每页显示 20 50 100
Down-regulation and Clinical Implication of Galectin-9 Levels in Patients with Acute Coronary Syndrome and Chronic Kidney Disease 被引量:2
1
作者 Jian-hua XIE Rui-rui ZHU +2 位作者 Li ZHAO Yu-cheng ZHONG Qiu-tang ZENG 《Current Medical Science》 SCIE CAS 2020年第4期662-670,共9页
Summary:In various autoimmune diseases,Galecin-9(Gal-9)has been shown to regulate the T-cell balance by decreasing Th1 and Th17,while increasing the number of regulatory T cells(Tregs).However,the role of Gal-9 in the... Summary:In various autoimmune diseases,Galecin-9(Gal-9)has been shown to regulate the T-cell balance by decreasing Th1 and Th17,while increasing the number of regulatory T cells(Tregs).However,the role of Gal-9 in the patients with acute coronary syndrome(ACS)and chronic kidney disease(CKD)remains unclear.This study aims to measure the Gal-9 levels in serum and peripheral blood mononuclear cells(PBMCs)in patients with ACS plus CKD and examine their clinical implication.The serum levels of Gal-9 were determined by enzyme linked immunosorbent assay(ELISA),the expression levels of Gal-9,Tim-3,and Foxp3 mRNA in PBMCs were detected by real-time reverse transcription-polymerase chain reaction(RT-PCR),and the expression of Gal-9 on the surface of PBMCs and in PBMCs was analyzed by flow cytometry.Furthermore,the correlation of serum Gal-9 levels with anthropometric and biochemical variables in patients with ACS plus CKD was analyzed.The lowest levels of Gal-9 in serum and PBMCs were found in the only ACS group,followed by the ACS+CKD group,and the normal coronary artery(NCA)group,.respectively.Serum Gal-9 levels were increased along with the progression of glomerular filtration rate(GFR)categories of G1 to G4.Additionally,serum Gal-9 levels were negatively correlated with high-sensitivity C-reactive protein(hs-CRP),estimated GFR(eGFR),and lipoprotein(a),but positively with creatinine,age,osmotic pressure,and blood urea nitrogen(BUN).Notably,serum Gal-9 was independently associated with hs-CRP,osmotic pressure,and lipoprotein(a).Furthermore,serum Gal-9 levels were elevated in patients with type 2 diabetes(T2DM)and impaired glucose tolerance(IGT)in ACS group.It was suggested that the levels of Gal-9 in serum and PBMCs were decreased in patients with simple ACS and those with ACS plus CKD,and hs-CRP,eGFR,osmotic pressure and T2DM may have an influence on serum Gal-9 levels. 展开更多
关键词 GALECTIN-9 inflammation acute coronary syndrome chronic kidney disease
下载PDF
Clinical and pathophysiological understanding of the hepatorenal syndrome:Still wrong or still not exactly right? 被引量:1
2
作者 Benjamin Wilde Ali Canbay Antonios Katsounas 《World Journal of Clinical Cases》 SCIE 2023年第6期1261-1266,共6页
The hepatorenal syndrome(HRS)is one major extrahepatic complication of endstage liver diseases.While circulatory dysregulation is considered as primary etiology for HRS,cirrhosis-related(systemic)inflammation and/or c... The hepatorenal syndrome(HRS)is one major extrahepatic complication of endstage liver diseases.While circulatory dysregulation is considered as primary etiology for HRS,cirrhosis-related(systemic)inflammation and/or cardial dysfunction may also play a key pathogenic role in HRS development.Exclusion of other causes of acute kidney injury(AKI)is required for diagnosis of HRS-AKI by the definition of the International Club of Ascites.However,the pathophysiology of HRS is not understood completely and there are still limited therapeutic options.Reversibility of renal dysfunction after liver transplantation indicates that HRS-AKI is a functional disorder caused by altered cellular function.The interplay between systemic inflammation and the onset of kidneyrelated hypometabolism may have a key role and needs to be studied in depth.This minireview challenges simplified views of the HRS in the context of diagnostics and therapy stressing the need for further evidence to advance the knowledge on this syndrome. 展开更多
关键词 Hepatorenal syndrome Liver disease CIRRHOSIS inflammation chronic kidney disease acute kidney injury
下载PDF
Driving role of macrophages in transition from acute kidney injury to chronic kidney disease 被引量:4
3
作者 Xiaoming Meng Juan Jin Hui Yao Lan 《Chinese Medical Journal》 SCIE CAS CSCD 2022年第7期757-766,共10页
Acute kidney injury(AKI),characterized by acute renal dysfunction,is an increasingly common clinical problem and an important risk factor in the subsequent development of chronic kidney disease(CKD).Regardless of the ... Acute kidney injury(AKI),characterized by acute renal dysfunction,is an increasingly common clinical problem and an important risk factor in the subsequent development of chronic kidney disease(CKD).Regardless of the initial insults,the progression of CKD after AKI involves multiple types of cells,including renal resident cells and immune cells such as macrophages.Recently,the involvements of macrophages in AKI-to-CKD transition have garnered significant attention.Furthermore,substantial progress has also been made in elucidating the pathophysiological functions of macrophages from the acute kidney to repair or fibrosis.In this review,we highlight current knowledge regarding the roles and mechanisms of macrophage activation and phenotypic polarization,and transdifferentiation in the development of AKI-to-CKD transition.In addition,the potential of macrophage-based therapy for preventing AKI-to-CKD transition is also discussed. 展开更多
关键词 acute kidney injury chronic kidney disease MACROPHAGE inflammation REPAIR Macrophage-based therapy
原文传递
姜黄素对内毒素所致肾脏炎症的抑制作用 被引量:7
4
作者 仲芳 陈慧 +3 位作者 韩琳 靳远萌 王伟铭 陈楠 《中国中西医结合肾病杂志》 2009年第11期948-951,共4页
目的:肾脏的急慢性炎症与肾脏疾病的进展密切相关,本研究拟探讨姜黄素对内毒素(LPS)所致肾脏炎症的抑制作用。方法:SPF级昆明种小鼠40只,鼠龄6~8周,体重20~25g。小鼠分为3组:(1)正常对照组:腹腔注射生理盐水;(2)模型组(LPS组):腹腔注... 目的:肾脏的急慢性炎症与肾脏疾病的进展密切相关,本研究拟探讨姜黄素对内毒素(LPS)所致肾脏炎症的抑制作用。方法:SPF级昆明种小鼠40只,鼠龄6~8周,体重20~25g。小鼠分为3组:(1)正常对照组:腹腔注射生理盐水;(2)模型组(LPS组):腹腔注射LPS(1mg/kg和5mg/kg);(3)治疗组(LPS+姜黄素):动物先腹腔注射姜黄素(1mg/kg或5mg/kg)3d,然后腹腔注射LPS1mg/kg或5mg/kg。于处理后6h取材,切取部分肾组织用10%甲醛固定,HE染色,进行病理学观察。部分肾组织用于MCP-1mRNA检测。将肾小管上皮细胞(HK-2细胞)培养于KSF培养液中,设正常对照组给予正常培养液,LPS刺激组(1ng/ml,100ng/ml和10μg/ml),LPS刺激+姜黄素(5μmol/L和50μmol/L)处理组,分别培养4h和24h后收集细胞,应用Real-timePCR检测各组细胞MCP-1的表达。ELISA检测细胞培养上清液中MCP-1的表达。EMSA检测肾小管上皮细胞NF-κB的活性。结果:腹腔注射LPS(1mg/kg和5mg/kg)虽未引起光镜下肾脏组织的病理改变,但可显著增加小鼠肾脏MCP-1 mRNA的表达,分别增加20倍和26倍,而姜黄素处理可降低LPS所诱导的肾脏MCP-1 mRNA的表达,尤以LPS(1mg/kg)+姜黄素(1mg/kg)为明显(下降至基础值的2.5倍)。应用不同浓度的LPS刺激HK-2细胞4h,HK-2细胞MCP-1 mRNA表达量显著增加,且呈剂量依赖的效应(分别增加1.60、2.15和14.7倍)。而以100ng/ml的LPS刺激HK-2细胞4h,观察姜黄素的干预作用,可见不同浓度的姜黄素(5μmol/L和50μmol/L)可显著抑制LPS所诱导的HK-2细胞MCP-1 mRNA的表达,且以50μmol/L姜黄素干预组为明显。同时ELSA检测细胞上清液中MCP-1的表达结果相似。EMSA结果显示NF-κB的DNA结合活性随LPS的浓度增加而增加,而应用姜黄素预处理后,由LPS所诱导的增高的NF-κB的DNA结合活性随之下降。结论:早期给予姜黄素治疗,能明显改善LPS诱导的小鼠肾脏趋化因子MCP-1的表达,从而发挥其肾脏损伤的保护功能;而体外研究表明姜黄素可抑制LPS所诱导的肾小管上皮细胞MCP-1表达,其作用可能与抑制细胞NF-κB的活性有关。 展开更多
关键词 姜黄素 内毒素 急慢性炎症 肾脏疾病
下载PDF
The role of high mobility group box 1(HMGB1)in the pathogenesis of kidney diseases 被引量:31
5
作者 Qingjie Chen Xiaofeng Guan +2 位作者 Xiaocong Zuo Jianglin Wang Wenjun Yin 《Acta Pharmaceutica Sinica B》 SCIE CAS CSCD 2016年第3期183-188,共6页
High mobility group box 1 (HMGB1) is a nuclear protein that can bind to DNA and act as a co-factor for gene transcription. When released into extracellular fluid, it plays a proinflammatory role by acting as a damage-... High mobility group box 1 (HMGB1) is a nuclear protein that can bind to DNA and act as a co-factor for gene transcription. When released into extracellular fluid, it plays a proinflammatory role by acting as a damage-associated molecular pattern molecule (DAMP) (also known as an alarmin) to initiate innate immune responses by activating multiple cell surface receptors such as the receptor for advanced glycation end-products (RAGE) and toll-like receptors (TLRs), TLR2, TLR4 or TLR9. This proinflammatory role is now considered to be important in the pathogenesis of a wide range of kidney diseases whether they result from hemodynamic changes, renal tubular epithelial cell apoptosis, kidney tissue fibrosis or inflammation. This review summarizes our current understanding of the role of HMGB1 in kidney diseases and how the HMGB1-mediated signaling pathway may constitute a new strategy for the treatment of kidney diseases. (C) 2016 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. 展开更多
关键词 High mobility group box 1 inflammation acute kidney injury chronic kidney disease Diabetic nephropthy Antineutrophil cytoplasmic autoantibody-associated vasculitis Clear cell renal cell carcinoma NEPHRITIS
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部